These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Chizh BA; O'Donnell MB; Napolitano A; Wang J; Brooke AC; Aylott MC; Bullman JN; Gray EJ; Lai RY; Williams PM; Appleby JM Pain; 2007 Nov; 132(1-2):132-41. PubMed ID: 17659837 [TBL] [Abstract][Full Text] [Related]
10. Double-blinded randomized prospective trial of intranasal capsaicin treatment for nonallergic rhinitis. Zebda D; Jiang ZY; Gibson MM; Pham C; Ahmadi S; Floren S; Yao WC; Citardi MJ; Luong AU Int Forum Allergy Rhinol; 2021 Jan; 11(1):24-30. PubMed ID: 33045140 [TBL] [Abstract][Full Text] [Related]
11. Enhanced chemosensory sensitivity in patients with idiopathic rhinitis and its reversal by nasal capsaicin treatment. Van Gerven L; Alpizar YA; Steelant B; Callebaut I; Kortekaas Krohn I; Wouters M; Vermeulen F; Boeckxstaens G; Talavera K; Hellings PW J Allergy Clin Immunol; 2017 Aug; 140(2):437-446.e2. PubMed ID: 28389389 [TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis. Bernstein JA; Davis BP; Picard JK; Cooper JP; Zheng S; Levin LS Ann Allergy Asthma Immunol; 2011 Aug; 107(2):171-8. PubMed ID: 21802026 [TBL] [Abstract][Full Text] [Related]
14. Azelastine desensitization of transient receptor potential vanilloid 1: a potential mechanism explaining its therapeutic effect in nonallergic rhinitis. Singh U; Bernstein JA; Haar L; Luther K; Jones WK Am J Rhinol Allergy; 2014; 28(3):215-24. PubMed ID: 24980233 [TBL] [Abstract][Full Text] [Related]
15. A randomised trial evaluating the effects of the TRPV1 antagonist SB705498 on pruritus induced by histamine, and cowhage challenge in healthy volunteers. Gibson RA; Robertson J; Mistry H; McCallum S; Fernando D; Wyres M; Yosipovitch G PLoS One; 2014; 9(7):e100610. PubMed ID: 25047038 [TBL] [Abstract][Full Text] [Related]
16. Safety, Pharmacokinetics, and Pharmacodynamics Study in Healthy Subjects of Oral NEO6860, a Modality Selective Transient Receptor Potential Vanilloid Subtype 1 Antagonist. Brown W; Leff RL; Griffin A; Hossack S; Aubray R; Walker P; Chiche DA J Pain; 2017 Jun; 18(6):726-738. PubMed ID: 28188907 [TBL] [Abstract][Full Text] [Related]